Home  /  Latin America and the Caribbean  /  PER

Peru

Our project reads two Peruvian publishers. The Demographic and Family Health Survey (ENDES) of the national statistics institute (INEI) gives the share of people aged 15 to 49 who had an HIV test in the last 12 months, nationally from the second half of 2013 and for 26 departments from 2014, with 95 per cent confidence intervals. The HIV situation room of CDC Peru, the national epidemiology centre of the Ministry of Health, gives the HIV cases notified for 2019 to 2025, AIDS cases included, for the 25 departments and nationally by sex. The situation room enters the panel only where the 25 departments sum to the national count in every year, and CDC Peru revises past years at every monthly update.

140,000
People living with HIV, 2025
WHO Global Health Observatory
79.0%
On antiretroviral treatment, 2025
WHO Global Health Observatory
$566k
United States HIV disbursements, 2026
ForeignAssistance.gov
$10.3m
External HIV financing, all donors, 2024
OECD Creditor Reporting System
External HIV financing
OECD CRS · ForeignAssistance.gov
$0$10m$20m200220052008201120142017202020232026$10.3m$732k$9.5m$566k
  • All donors
  • United States, OECD record
  • The Global Fund
  • United States, self-reported
YearAll donorsUnited States, OECD recordThe Global FundUnited States, self-reported
2002 $494k — — —
2003 $1.2m — $964k $300k
2004 $5.9m $243k $5.5m $460k
2005 $7.2m $1.1m $5.6m $729k
2006 $8.8m $623k $7.7m $876k
2007 $12.2m $2.3m $8.7m $2.0m
2008 $11.6m $1.8m $7.9m $1.9m
2009 $19.0m $1.6m $15.7m $1.6m
2010 $12.4m $2.2m $8.6m $2.2m
2011 $5.7m $1.6m $2.9m $1.8m
2012 $6.1m $1.0m $4.2m $1.1m
2013 $2.3m $357k $966k $533k
2014 $3.6m $374k $2.8m $225k
2015 $1.2m $243k — $291k
2016 $4.5m $239k $3.5m $394k
2017 $4.0m $308k $2.9m $325k
2018 $2.0m $263k $1.6m $263k
2019 $7.3m $521k $6.6m $511k
2020 $2.6m $250k $2.2m $300k
2021 $984k $260k $673k $462k
2022 $9.7m $1.1m $8.5m $1.4m
2023 $11.5m $1.5m $9.7m $2.6m
2024 $10.3m $732k $9.5m $1.4m
2025 — — — $1.5m
2026 — — — $566k

25 rows, as drawn above. Values are rounded for display, and the download gives the unrounded values.

Disbursements reported for the country. The OECD record and the United States self-reported record are drawn separately. The two records cover the same United States disbursements, but the OECD record is filed by calendar year and the self-reported record by United States fiscal year.

People living with HIV and people on treatment
UNAIDS AIDSinfo
050k100k150k200020032006200920122015201820212024130,000100,000
  • People living with HIV
  • People on treatment
YearPeople living with HIVPeople living with HIV (lower)People living with HIV (upper)People on treatment
2000 61,000 53,000 74,000 —
2001 62,000 54,000 74,000 —
2002 62,000 54,000 73,000 —
2003 62,000 53,000 73,000 —
2004 62,000 54,000 72,000 —
2005 62,000 54,000 72,000 —
2006 62,000 54,000 72,000 —
2007 63,000 55,000 73,000 —
2008 63,000 56,000 74,000 —
2009 64,000 57,000 75,000 —
2010 66,000 58,000 76,000 20,000
2011 68,000 60,000 78,000 22,000
2012 70,000 62,000 81,000 28,000
2013 73,000 64,000 84,000 28,000
2014 76,000 67,000 88,000 33,000
2015 79,000 70,000 92,000 35,000
2016 83,000 74,000 97,000 44,000
2017 88,000 78,000 100,000 49,000
2018 94,000 84,000 110,000 58,000
2019 99,000 88,000 110,000 68,000
2020 100,000 92,000 120,000 72,000
2021 110,000 97,000 130,000 80,000
2022 110,000 100,000 130,000 88,000
2023 120,000 110,000 140,000 91,000
2024 130,000 110,000 140,000 100,000

25 rows, as drawn above. Values are rounded for display, and the download gives the unrounded values.

Modelled estimates. The shaded area is the published uncertainty interval around the number of people living with HIV, because a single estimate without the interval would overstate the precision of the model.

The treatment cascade
UNAIDS AIDSinfo
20%40%60%80%2010201220142016201820202022202487.0%80.0%66.0%
  • Diagnosed
  • On treatment
  • Virally suppressed
YearDiagnosedOn treatmentVirally suppressed
2010 — 30.0% —
2011 — 32.0% —
2012 — 39.0% —
2013 — 39.0% —
2014 — 44.0% —
2015 — 44.0% —
2016 — 52.0% —
2017 70.0% 56.0% 43.0%
2018 72.0% 62.0% 48.0%
2019 75.0% 68.0% 52.0%
2020 78.0% 69.0% 55.0%
2021 80.0% 73.0% 58.0%
2022 83.0% 77.0% 57.0%
2023 86.0% 76.0% 66.0%
2024 87.0% 80.0% 66.0%

15 rows, as drawn above. Values are rounded for display, and the download gives the unrounded values.

Every line is a percentage of all people living with HIV, so the three lines share a denominator and can be compared directly. Viral suppression in the figure is the share of all people living with HIV who are virally suppressed, and not the narrower third 95 target, which counts only people on treatment.

Data-quality flags on Peru

Number of people on ART (PEPFAR MER TX_CURR), 2022 (PEPFAR Panorama Spotlight). The value moved from 173 in 2021 to 554 in 2022, a change of more than threefold in a single year. The move from 173 to 554 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2021 and 2022 are not comparable. Check the figures by reporting organisation before reading a trend across 2021 and 2022.

Number of people on ART (PEPFAR MER TX_CURR), 2023 (PEPFAR Panorama Spotlight). The value moved from 554 in 2022 to 1,752 in 2023, a change of more than threefold in a single year. The move from 554 to 1,752 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.

Number of PLHIV virally suppressed (VL<1000), 2022 (PEPFAR Panorama Spotlight). The value moved from 8 in 2021 to 306 in 2022, a change of more than threefold in a single year. The move from 8 to 306 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2021 and 2022 are not comparable. Check the figures by reporting organisation before reading a trend across 2021 and 2022.

Number of PLHIV virally suppressed (VL<1000), 2023 (PEPFAR Panorama Spotlight). The value moved from 306 in 2022 to 1,381 in 2023, a change of more than threefold in a single year. The move from 306 to 1,381 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.

Sources of the figures for Peru

3,934 rows

SourceTypeRowsIndicators YearsRead fromRetrieved
UNICEF HIV/AIDS dataset Modelled estimate 1,376 5 2010–2025 sdmx.data.unicef.org 2026-10-20
UNAIDS AIDSinfo Modelled estimate 808 29 2000–2024 aidsinfo.unaids.org 2026-10-20
Peru Demographic and Family Health Survey (ENDES) Survey 387 1 2013–2025 inei.gob.pe 2026-10-13
WHO Global Health Observatory Modelled estimate 265 12 2000–2025 ghoapi.azureedge.net 2026-10-12
CDC Peru HIV situation room (Sala VIH) Programme record 196 1 2019–2025 app7.dge.gob.pe 2026-10-28
Demographic and Health Surveys Survey 184 2 2000–2012 api.dhsprogram.com 2026-10-16
WHO Global Tuberculosis Programme Programme record 178 17 2000–2025 extranet.who.int 2026-10-16
ForeignAssistance.gov Expenditure account 67 4 2003–2026 foreignassistance.gov 2026-10-29
OECD Creditor Reporting System Expenditure account 65 3 2002–2024 sdmx.oecd.org 2026-10-12
IATI, through d-portal Expenditure account 61 3 2000–2026 d-portal.org 2026-10-12
Global Fund Data Service Programme record 53 5 2017–2025 fetch.theglobalfund.org 2026-10-12
World Bank Open Data Modelled estimate 51 2 2000–2025 api.worldbank.org 2026-10-12
PAHO Core Indicators Programme record 48 1 2009–2025 opendata.paho.org 2026-10-13
UNAIDS Global AIDS Monitoring expenditure database Expenditure account 40 10 2020–2024 hivfinancial.unaids.org 2026-10-12
WHO HIV testing services dashboard Programme record 36 4 2018–2024 eic-database-290813.ew.r.appspot.com 2026-10-14
PEPFAR Panorama Spotlight Programme record 26 6 2021–2025 data.pepfar.gov 2026-10-12
PEPFAR budgets and expenditure Expenditure account 25 6 2021–2025 data.pepfar.gov 2026-10-12
PEPFAR testing by modality Programme record 22 6 2021–2025 data.pepfar.gov 2026-10-12
PEPFAR results by funding agency Programme record 15 3 2021–2025 data.pepfar.gov 2026-10-12
PAHO Interactive HIV Data Dashboard Programme record 10 2 2018–2025 paho.org 2026-10-14
PEPFAR commodity procurement plans Expenditure account 8 4 2021–2024 data.pepfar.gov 2026-10-12
UNAIDS Data 2025 country databook Expenditure account 6 2 2020–2023 aidsinfo.unaids.org 2026-10-15
Global Fund allocations Expenditure account 4 1 2017–2026 fetch.theglobalfund.org 2026-10-12
PEPFAR human resources for health inventory Expenditure account 3 3 2025 data.pepfar.gov 2026-10-12

Indicators held

91 of 150

IndicatorDomainUnitRows YearsSourcesMost recent value
Actual expenditure on collaborative TB/HIV activities Financing USD 8 2017–2024 WHO Global Tuberculosis Programme $6.8m (2024)
Budget required for collaborative TB/HIV activities Financing USD 8 2018–2025 WHO Global Tuberculosis Programme $6.8m (2025)
Country-reported HIV expenditure, all sources Financing USD 10 2013–2024 UNAIDS AIDSinfo, UNAIDS Global AIDS Monitoring expenditure database $100.0m (2024)
Domestic funding received by the national TB programme Financing USD 8 2017–2024 WHO Global Tuberculosis Programme $136.6m (2024)
Domestic public HIV expenditure Financing USD 7 2020–2024 UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database $90.7m (2024)
Expected Global Fund funding for the national TB programme Financing USD 8 2018–2025 WHO Global Tuberculosis Programme $2.6m (2025)
Expected USAID funding for the national TB programme Financing USD 5 2018–2023 WHO Global Tuberculosis Programme $0 (2023)
Expected domestic funding for the national TB programme Financing USD 8 2018–2025 WHO Global Tuberculosis Programme $153.7m (2025)
Expected funding for collaborative TB/HIV activities Financing USD 8 2018–2025 WHO Global Tuberculosis Programme $6.8m (2025)
External HIV financing (all donors, ODA) Financing USD 23 2002–2024 OECD Creditor Reporting System $10.3m (2024)
External HIV financing from governments other than the United States (IATI) Financing USD 26 2000–2025 IATI, through d-portal $0 (2025)
External HIV financing from multilateral bodies other than the Global Fund (IATI) Financing USD 12 2015–2026 IATI, through d-portal $35k (2026)
External HIV financing from the United States (ODA) Financing USD 45 2003–2026 ForeignAssistance.gov, OECD Creditor Reporting System $566k (2026)
Funding received for collaborative TB/HIV activities Financing USD 8 2017–2024 WHO Global Tuberculosis Programme $7.2m (2024)
Global Fund HIV allocation for a whole three-year cycle, not an annual figure Financing USD per three-year allocation cycle 4 2017–2026 Global Fund allocations 5,714,247 (2026)
Global Fund HIV disbursements to the country Financing USD 48 2003–2026 IATI, through d-portal, OECD Creditor Reporting System, UNAIDS Global AIDS Monitoring expenditure database $7.3m (2026)
Global Fund funding received by the national TB programme Financing USD 8 2017–2024 WHO Global Tuberculosis Programme $12.9m (2024)
HIV spending on TB/HIV co-infection Financing USD 4 2020–2024 UNAIDS Global AIDS Monitoring expenditure database $34k (2024)
HIV spending on critical enablers Financing USD 4 2020–2024 UNAIDS Global AIDS Monitoring expenditure database $137k (2024)
HIV spending on governance and sustainability Financing USD 4 2020–2024 UNAIDS Global AIDS Monitoring expenditure database $9.5m (2024)
HIV spending on prevention Financing USD 4 2020–2024 UNAIDS Global AIDS Monitoring expenditure database $43.0m (2024)
HIV spending on prevention of vertical transmission Financing USD 4 2020–2024 UNAIDS Global AIDS Monitoring expenditure database $7.3m (2024)
HIV spending on treatment, care and support Financing USD 4 2020–2024 UNAIDS Global AIDS Monitoring expenditure database $40.0m (2024)
International HIV expenditure (country-reported) Financing USD 7 2020–2024 UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database $9.3m (2024)
PEPFAR expenditure, HHS/CDC Financing USD 5 2021–2025 PEPFAR budgets and expenditure $1.0m (2025)
PEPFAR expenditure, USAID Financing USD 3 2021–2023 PEPFAR budgets and expenditure $750k (2023)
PEPFAR expenditure, all US agencies Financing USD 5 2021–2025 PEPFAR budgets and expenditure $1.0m (2025)
PEPFAR planned commodity procurement, like for like Financing USD 2 2021–2024 PEPFAR commodity procurement plans $47k (2024)
PEPFAR planned funding (budget), all US agencies Financing USD 5 2021–2025 PEPFAR budgets and expenditure $1.4m (2025)
PEPFAR planned funding, HHS/CDC Financing USD 5 2021–2025 PEPFAR budgets and expenditure $1.4m (2025)
PEPFAR planned funding, USAID Financing USD 2 2022–2023 PEPFAR budgets and expenditure $750k (2023)
PEPFAR planned procurement of antiretroviral drugs Financing USD 2 2021–2024 PEPFAR commodity procurement plans $0 (2024)
PEPFAR planned procurement of laboratory commodities Financing USD 2 2021–2024 PEPFAR commodity procurement plans $0 (2024)
PEPFAR planned procurement of rapid test kits Financing USD 2 2021–2024 PEPFAR commodity procurement plans $47k (2024)
PEPFAR spend on staff, human resources for health inventory Financing USD 1 2025 PEPFAR human resources for health inventory $630k (2025)
PEPFAR-funded staff delivering services, full-time equivalents Financing count 1 2025 PEPFAR human resources for health inventory 21 (2025)
PEPFAR-funded staff, full-time equivalents Financing count 1 2025 PEPFAR human resources for health inventory 41 (2025)
US HIV disbursements managed by Health and Human Services Financing USD 4 2023–2026 ForeignAssistance.gov $534k (2026)
US HIV disbursements managed by USAID Financing USD 20 2003–2026 ForeignAssistance.gov $0 (2026)
US HIV disbursements managed by other US agencies Financing USD 19 2008–2026 ForeignAssistance.gov $32k (2026)
USAID funding received by the national TB programme Financing USD 4 2017–2022 WHO Global Tuberculosis Programme $0 (2022)
% of ALL PLHIV who are virally suppressed Treatment cascade percent 17 2017–2025 UNAIDS AIDSinfo, WHO Global Health Observatory 70.0% (2025)
% of PLHIV on ART (second 95, PLHIV base) Treatment cascade percent 71 2000–2025 UNAIDS AIDSinfo, WHO Global Health Observatory 79.0% (2025)
% of PLHIV who have been diagnosed (first 95) Treatment cascade percent 19 2017–2025 UNAIDS AIDSinfo, WHO Global Health Observatory 85.0% (2025)
% of estimated HIV-positive incident TB cases on TB treatment and ART Treatment cascade percent 20 2003–2024 UNAIDS AIDSinfo 35.3% (2024)
% of people currently enrolled in HIV treatment started on TB preventive therapy Treatment cascade percent 3 2019–2024 UNAIDS AIDSinfo 4.0% (2024)
% of people living with HIV on ART who completed a course of TB preventive therapy Treatment cascade percent 2 2023–2024 UNAIDS AIDSinfo 86.4% (2024)
% of people newly enrolled in HIV treatment diagnosed with TB disease Treatment cascade percent 8 2014–2024 UNAIDS AIDSinfo 11.8% (2024)
% of people newly enrolled in HIV treatment started on TB preventive therapy Treatment cascade percent 8 2014–2024 UNAIDS AIDSinfo 32.0% (2024)
% of people on ART who are virally suppressed (third 95) Treatment cascade percent 9 2017–2025 WHO Global Health Observatory 89.0% (2025)
% of returned HIV test results that were positive Treatment cascade percent 30 2018–2024 UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard 0.4% (2024)
HIV tests performed at a health facility Treatment cascade count 5 2018–2025 PEPFAR testing by modality, WHO HIV testing services dashboard 560 (2025)
HIV tests performed through community outreach Treatment cascade count 7 2018–2025 PEPFAR testing by modality, WHO HIV testing services dashboard 4,638 (2025)
HIV tests performed with the result returned to the person Treatment cascade count 45 2018–2025 Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard 5,198 (2025)
HIV-exposed infants tested within two months of birth Treatment cascade percent 14 2011–2024 UNAIDS AIDSinfo 60.0% (2024)
HIV-positive TB patients started or continued on ART Treatment cascade count 22 2015–2025 Global Fund Data Service, WHO Global Tuberculosis Programme 996 (2025)
Key-population people tested for HIV (count over the period) Treatment cascade count 16 2020–2025 Global Fund Data Service By population group, sex or age only, to 2025
New HIV diagnoses with a CD4 count below 200 Treatment cascade percent 2 2018–2020 UNAIDS AIDSinfo 16.0% (2020)
Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS) Treatment cascade count 5 2021–2025 PEPFAR results by funding agency 112 (2025)
Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW) Treatment cascade count 5 2021–2025 PEPFAR results by funding agency 103 (2025)
Notified HIV cases, national case surveillance Treatment cascade count 247 2009–2025 CDC Peru HIV situation room (Sala VIH), PAHO Core Indicators, PAHO Interactive HIV Data Dashboard 9,112 (2025)
Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS) Treatment cascade count 10 2021–2025 PEPFAR Panorama Spotlight, PEPFAR testing by modality 112 (2025)
Number of PLHIV virally suppressed (VL<1000) Treatment cascade count 5 2021–2025 PEPFAR Panorama Spotlight 2,177 (2025)
Number of people on ART (PEPFAR MER TX_CURR) Treatment cascade count 83 2000–2025 Global Fund Data Service, PEPFAR Panorama Spotlight, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO Global Tuberculosis Programme 108,611 (2025)
PMTCT ART coverage among pregnant women with HIV Treatment cascade percent 31 2010–2025 UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset 78.0% (2025)
People aged 15 to 49 who had an HIV test in the last 12 months (household survey) Treatment cascade percent 387 2013–2025 Peru Demographic and Family Health Survey (ENDES) By population group, sex or age only, to 2025
People newly diagnosed at a health facility Treatment cascade count 1 2025 PEPFAR testing by modality 62 (2025)
People newly diagnosed through community outreach Treatment cascade count 5 2021–2025 PEPFAR testing by modality 50 (2025)
People newly enrolled on ART during the year Treatment cascade count 13 2014–2025 PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme 103 (2025)
People on ART at HHS/CDC-funded partners (MER TX_CURR) Treatment cascade count 5 2021–2025 PEPFAR results by funding agency 2,677 (2025)
People on ART on a dolutegravir-based regimen Treatment cascade percent 7 2022–2025 PAHO Interactive HIV Data Dashboard By population group, sex or age only, to 2025
Pregnant women tested for HIV in antenatal care Treatment cascade percent 8 2017–2024 UNAIDS AIDSinfo 98.0% (2024)
Pregnant women with HIV who received ARVs for PMTCT Treatment cascade count 31 2010–2025 UNAIDS AIDSinfo, WHO Global Health Observatory 1,083 (2025)
TB patients recorded as HIV-positive Treatment cascade count 15 2015–2024 WHO Global Tuberculosis Programme 1,618 (2024)
TB patients with an HIV test result recorded Treatment cascade count 15 2015–2024 WHO Global Tuberculosis Programme 29,329 (2024)
AIDS-related deaths Epidemic estimates count 681 2000–2025 UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory 1,100 (2025)
Deaths from TB among people living with HIV Epidemic estimates count 50 2000–2024 UNAIDS AIDSinfo, WHO Global Tuberculosis Programme 700 (2024)
HIV prevalence among a key population Epidemic estimates percent 4 2024 UNAIDS AIDSinfo By population group, sex or age only, to 2024
HIV prevalence, ages 15-49 Epidemic estimates percent 50 2000–2024 UNAIDS AIDSinfo, World Bank Open Data 0.4% (2024)
Incident TB cases among people living with HIV Epidemic estimates count 50 2000–2024 UNAIDS AIDSinfo, WHO Global Tuberculosis Programme 2,600 (2024)
New HIV infections Epidemic estimates count 585 2000–2025 UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory 6,600 (2025)
People living with HIV Epidemic estimates count 681 2000–2025 UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory 140,000 (2025)
Condom use at last higher-risk sex (household survey) Prevention and outreach percent 106 2000–2012 Demographic and Health Surveys By population group, sex or age only, to 2012
Key-population people reached by outreach (count over the period) Prevention and outreach count 16 2020–2025 Global Fund Data Service By population group, sex or age only, to 2025
Male condoms distributed in a year Prevention and outreach count 5 2019–2024 UNAIDS AIDSinfo 63,653,610 (2024)
People receiving PrEP Prevention and outreach count 7 2018–2024 PEPFAR Panorama Spotlight, UNAIDS AIDSinfo 5,300 (2024)
People with comprehensive correct knowledge of HIV (household survey) Prevention and outreach percent 78 2004–2009 Demographic and Health Surveys By population group, sex or age only, to 2009
Estimated pregnant women with HIV needing ARVs for PMTCT Population denominators count 31 2010–2025 UNAIDS AIDSinfo, WHO Global Health Observatory 1,400 (2025)
Estimated size of a key population Population denominators count 4 2024 UNAIDS AIDSinfo By population group, sex or age only, to 2024
Total population Population denominators count 26 2000–2025 World Bank Open Data 34,576,665 (2025)
Share of HIV-exposed infants who acquire HIV — percent 31 2010–2025 UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset 14.9% (2025)

Every row shown on the Peru page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.